but going We've all that a think in sense I'd efficacy marketplace. happy Sure. from to talk publicly perspective. data that, We from the in that's along of answer an six-month Yatin. be we're perspective efficacy said about to the of important,
over available, least at the believe we be the sustained-release months, is it's on out injectable because to for that any four of sufficient four announcing While showing efficacy that drugs approved, there, all minimum faricimab, now a products at data, efficacious we're or FDA a patients. has soon some be if that to number like really in four-month months it significant of planning show available not can are signs
minimum. the is in to our long. But implants be we the to order in last targeting and really been that's months target, we're So, the marketplace six successful think that
talk top And when the plan a we so have data six-month data line our efficacy set. full for about is to
expect gain remember, when in treated with first all two to patients. care, really first standard all get what they the AMD Wet Now, previously three of treated with of get first we months diagnosed Patients and is, vision injection. they they the are these
entered don't their really much who patients improve room there's the so we And study, the vision. to believe
the visual say that So quantitative. variability Visual acuity acuity. be And there's same roughly months. roughly, to acuities really surprisingly always six we I expect in at isn't visual
what system, We'd bit always And should just love in a it little that's up to improvement, letters see of so, but stable. in visual acuity there partially system. three little -- that's the noise But down, letters a is the be toxicity patient type be is either vision noise three having across significant see enrolled. in the reduction may efficacious of suggest would the don't on actually depends were we we we or that What which not a cohorts, problem. to want all some
and visual with patient OCT So for expect activity for subdural acuity say speaking. biomarker thing we remain the is rough nice same that look VEGF I'd stability. OCT for thickness. essentially a the relatively should stable,
or there a can up fluctuations of that of the XX, microns be little affect down. noise, forms, which Again a bit vision. little XX, of thickness in be at can XX have fluid the So necessarily you doesn't OCT may subretinal bit
then, rate. look overall for rescue the is And measures so the And we one also. OCT other stability of
there ability a is who patient vision decreasing for rescue sustained-release have Phase X AMD to to due For in Wet appears to the activity. increasing investigator all of and/or the these fluid
the rate the of rates that have kind of but, only product. to if which study the reasonable than add I say low, is that XX cohorts. I'd And a less a XX%, problem; -- is so, end if it's -- rescue showing think, potential rescue first real we hope And our the would no is also successful very again a three we with six amount. I of eyes the target here, There's that are is over months
in a have free do, we'll study implant improve be vision on going characteristics But have we're us conclusions on X, that. should able in efficacy the help with who whose if sense patients to that. little data to rescue And And case that into to I they the trials, guide upcoming will based of the And didn't. who and entry criteria or it's really believe draw Phase who able upcoming going how there'll strongly in be which or well done to able the the in be did do patients we be to OCT do on identify we'll we may that hard so, because studies. bit rates to that photographs efficacy believe in predict for the on that well
